Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the Clinical and Economic Outcomes Associated With Exenatide Versus Basal Insulin in People With Type 2 Diabetes

Trial Profile

Evaluation of the Clinical and Economic Outcomes Associated With Exenatide Versus Basal Insulin in People With Type 2 Diabetes

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Feb 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exenatide (Primary) ; Insulin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors AstraZeneca

Most Recent Events

  • 01 Feb 2018 Primary endpoint (Changes from baseline in composite outcomes of HbA1c7.0% and weight reduction) has been met as per the results published in the Diabetes Therapy.
  • 01 Feb 2018 Primary endpoint (Changes from baseline in HbA1c (%)) has not been met as per the results published in the Diabetes Therapy.
  • 01 Feb 2018 Primary endpoint (Changes from baseline in weight (kg)) has been met as per the results published in the Diabetes Therapy.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top